eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
2/2014
vol. 6
 
Share:
Send email
Share:
abstract:

Original paper
Impact of intraoperative MRI/TRUS fusion on dosimetric parameters in cT3a prostate cancer patients treated with high-dose-rate real-time brachytherapy

Alfonso Gomez-Iturriaga
,
Juanita Crook
,
Francisco Casquero
,
Claudia Carvajal
,
Arantxa Urresola
,
Begońa Canteli
,
Ana Ezquerro
,
Eduardo Hortelano
,
Jon Cacicedo
,
Jose Maria Espinosa
,
Fernando Perez
,
Pablo Minguez
,
Pedro Bilbao

J Contemp Brachytherapy 2014; 6, 2: 154–160
DOI: https://doi.org/10.5114/jcb.2014.43299
Online publish date: 2014/06/09
View full text Get citation
 
Purpose: The purpose of this study was to evaluate the impact of intraoperative MRI/TRUS fusion procedure in cT3a prostate cancer patients treated with high-dose-rate (HDR) real-time brachytherapy.

Material and methods: Prostate gland, dominant intraprostatic lesions (DILs), and extracapsular extension (ECE) were delineated in the pre-brachytherapy magnetic resonance images (MRI) of 9 consecutive patients. The pre-implant P-CTVUS (prostate clinical target volume) was defined as the prostate seen in the transrectal ultrasound (TRUS) images. The CTVMR includedthe prostate with the ECE image (ECE-CTV) as defined on the MRI. Two virtual treatment plans were performed based on the MRI/TRUS fusion images, the first one prescribing 100% of the dose to the P-PTVUS, and the second prescribing to the PTVMR. The implant parameters and dose-volume histogram (DVH) related parameters of the prostate, OARs, and ECE were compared between both plans.

Results: Mean radial distance of ECE was 3.6 mm (SD: 1.1). No significant differences were found between prostate V100, V150, V200, and OARs DVH-related parameters between the plans. Mean values of ECE V100, V150, and V200 were 85.9 % (SD: 15.1), 18.2 % (SD: 17.3), and 5.85 % (SD: 7) when the doses were prescribed to the PTVUS, whereas ECE V100, V150, and V200 were 99.3 % (SD: 1.2), 45.8 % (SD: 22.4), and 19.6 % (SD: 12.6) when doses were prescribed to PTVMR (p = 0.028, p = 0.002 and p = 0.004, respectively).

Conclusions: TRUS/MRI fusion provides important information for prostate brachytherapy, allowing for better coverage and higher doses to extracapsular disease in patients with clinical stage T3a.
keywords:

extracapsular extension, high-dose-rate brachytherapy, MRI/TRUS fusion, prostate cancer

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.